Skip to Content
Merck
CN

Key Documents

View All Documentation

SML2101

Fosamprenavir calcium

≥98% (HPLC)

Synonym(s):

Calcium (3S) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1 -benzyl-2-(phosphonooxy)propylcarbamate, GW433908

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C25H34N3O9PS · Ca
CAS Number:
226700-81-8
Molecular Weight:
623.67
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD08141843
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear (warmed)

storage temp.

−20°C

SMILES string

[O-]P(O[C@H](CN(CC(C)C)S(C1=CC=C(N)C=C1)(=O)=O)[C@@H](NC(O[C@@H]2COCC2)=O)CC3=CC=CC=C3)([O-])=O.[Ca+2]

InChI

1S/C25H36N3O9PS.Ca/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21;/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32);/q;+2/p-2/t21-,23-,24+;/m0./s1

InChI key

PMDQGYMGQKTCSX-HQROKSDRSA-L

Biochem/physiol Actions

Fosamprenavir calcium is an HIV protease inhibitor anti-retroviral. It is a water soluble phosphate ester prodrug of amprenavir, the active agent.
HIV Protease Inhibitor; Antiretroviral

Still not finding the right product?

Explore all of our products under Fosamprenavir calcium

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000148214
0000148214
0000103764
0000028913
0000028912

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Lisa L Ross et al.
The open AIDS journal, 9, 38-44 (2015-07-15)
Treatment-emergent mutations and drug resistance were analyzed in virus from HIV-infected children meeting virologic failure (VF) criteria over 48 weeks following treatment with unboosted fosamprenavir or fosamprenavir/ritonavir-containing regimens in studies APV20002 and APV29005. Both antiretroviral therapy (ART)-naïve and ART-experienced patients
Paola Nasta et al.
HIV clinical trials, 17(3), 96-108 (2016-04-30)
Safety and tolerability evaluation of adapted dose regimens containing fosamprenavir/ritonavir (FPV/r) in HIV-infected subjects with viral hepatitis co-infection. A retrospective multicohort analysis was conducted. Subjects from three European cohorts who started FPV/r or lopinavir/ritonavir (LPV/r) as a comparator contributed data

Global Trade Item Number

SKUGTIN
SML2101-25MG04061835302581
SML2101-5MG04061835302598